BUSINESS

• Shionogi to Cut 200 Jobs via Voluntary Buyout Program
  July 11, 2023

• Japan Ethical Drug Sales Up 7.2% in May: Crecon
  July 10, 2023

• Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
  July 10, 2023

• Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
  July 7, 2023

• Meiji/Zeria Grabs Thai Approval for Functional Dyspepsia Drug
  July 7, 2023

• Astellas’ 1st-in-Class Gastric Cancer Med Bags Priority Review in US
  July 7, 2023

• Opdivo Extends Streak of Best-Seller Title to 18 Months: Encise
  July 7, 2023

• FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
  July 7, 2023

• Taiho’s FGFR Inhibitor Lytgobi Grabs Conditional OK in Europe
  July 6, 2023

• Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
  July 5, 2023

• Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
  July 5, 2023

• Shionogi Files Xofluza for Pediatric Indication in Taiwan
  July 5, 2023

• Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan
  July 5, 2023

• Nippon Shinyaku’s DMD Drug Gets Rare Pediatric Disease Tag in US
  July 5, 2023

• Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
  July 5, 2023

• Eisai CEO Confident on US Full Approval for Leqembi
  July 5, 2023

• Teijin, Axcelead Seal Definitive Accord to Form Drug Discovery JV
  July 4, 2023

• Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
  July 4, 2023

• AstraZeneca Seeks Label Expansion for Synagis in Japan
  July 4, 2023

• Kissei Adopts Iktos’ AI-Powered Drug Discovery System
  July 4, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• 145
• 146
• …
• Next ›
• 最終 »